

## AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior listings and versions of claims in this application.

1. (Original) A clonal lentogenic oncolytic strain of Newcastle Disease Virus (NDV) comprising the DNA nucleotide sequence of SEQ ID NO: 1 encoding for the fusion (F) gene and at least part of the hemagglutinin-neuraminidase (HN) gene.
2. (Currently Amended) A pharmaceutical composition for the treatment of cancer comprising as an active ingredient a lentogenic oncolytic strain of [[NDV]] Newcastle Disease Virus (NDV).
3. (Currently Amended) The pharmaceutical composition [[of]] according to claim 2 further comprising a suitable carrier.
4. (Currently Amended) The composition according to claim 2 wherein the lentogenic strain of NDV is the HUI strain.
5. (Original) The composition according to claim 4 comprising  $10^6 - 10^{12}$  EID<sub>50</sub> per unit dose.
6. (Original) The composition according to claim 2 further comprising at least one isolated viral glycoprotein having oncolytic activity.
7. (Original) The composition according to claim 6 wherein the at least one viral glycoprotein is from NDV.
8. (Original) The composition according to claim 7 wherein the at least one viral glycoprotein is the F glycoprotein of NDV.
9. (Original) The composition according to claim 7 wherein the at least one viral glycoprotein is the HN glycoprotein of NDV.
10. (Currently Amended) The composition according to claim [claims] 7 further comprising the F glycoprotein and hemagglutinin-neuraminidase (HN) [[HN]] glycoprotein of NDV.

11. (Currently Amended) The composition according to claim [claims] 7 wherein the viral glycoprotein is from a velogenic strain of NDV.
12. (Currently Amended) The composition according to claim [claims] 7 wherein the viral glycoprotein is from a mesogenic strain of NDV.
13. (Currently Amended) The composition according to claim [claims] 7 wherein the viral glycoprotein is from a lentogenic strain of NDV.
14. (Original) The composition according to claim 13 wherein the lentogenic strain of NDV is the HUI strain.
15. (Original) A composition for the treatment of cancer comprising at least one isolated viral glycoprotein or a subunit or analog thereof having oncolytic activity and a suitable carrier.
16. (Currently Amended) The composition according to claim 15 wherein the at least one viral glycoprotein is from Newcastle Disease Virus (NDV) [[NDV]].
17. (Currently Amended) The composition according to claim 16 wherein the at least one viral glycoprotein is the [[F]] fusion gene glycoprotein of Newcastle Disease Virus (NDV) [[NDV]].
18. (Currently Amended) The composition according to claim 16 wherein the at least one viral glycoprotein is the hemagglutinin-neuraminidase [[HN]] glycoprotein of NDV.
19. (Currently Amended) The composition according to claim 15 further comprising the F glycoprotein and hemagglutinin-neuraminidase [[HN]] glycoprotein of Newcastle Disease Virus (NDV) [[NDV]].
20. (Original) The composition according to claim 16 wherein the viral glycoprotein is from a velogenic strain of NDV.
21. (Original) The composition according to claim 16 wherein the viral glycoprotein is from a mesogenic strain of NDV.
22. (Original) The composition according to claim 16 wherein the viral glycoprotein is from a lentogenic strain of NDV.
23. (Currently Amended) The composition according to claim 22 wherein the lentogenic strain of NDV is the HUI strain.

24. (Original) A method for treating cancer in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 2.
25. (Original) The method of claim 24 wherein the step of administering is selected from intravenous, oral, buccal, intranasal, inhalation, topical application to a mucosal membrane or injection, including intradermal, intrathecal, intracisternal, and intralesional injection.
26. (Currently Amended) The method ~~[[according to]]~~ of claim 24 wherein the step of administering comprises locally administering the composition to a tumor or in its vicinity.
27. (Currently Amended) The method ~~[[according to]]~~ of claim 24 wherein the composition comprises a lentogenic oncolytic strain of NDV.
28. (Currently Amended) The method ~~[[according to]]~~ of claim 27 wherein the lentogenic oncolytic strain of NDV is the HUI strain.
29. (Currently Amended) The method ~~[[according to]]~~ of claim 28 wherein the ~~step of administering comprises administering the HUI strain of NDV in a range of 20 EID<sub>50</sub>/cell to 2000 EID<sub>50</sub>/cell~~ composition comprises 10<sup>6</sup>–10<sup>12</sup> EID<sub>50</sub> per unit dose.
30. (New) The method of claim 28 wherein the step of administering comprises administering the HUI strain of NDV in a range of 20 EID<sub>50</sub>/cell to 2000 EID<sub>50</sub>/cell.
31. (Currently Amended) A method for treating cancer in a patient which comprises administering to the patient ~~in need thereof~~ a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a lentogenic oncolytic strain of Newcastle Disease Virus (NDV) and at least one isolated polynucleotide encoding at least one viral glycoprotein polypeptide, or an analog or subunit thereof having oncolytic activity.
32. (Currently Amended) The method of claim 31, wherein the lentogenic oncolytic strain of NDV is the HUI strain ~~at least one isolated polynucleotide encodes the F glycoprotein of Newcastle Disease Virus.~~

33. (Currently Amended) The method of claim 31, wherein the at least one ~~isolated polynucleotide encodes the HN glycoprotein of Newcastle Disease Virus~~ viral glycoprotein is from NDV.
34. (Currently Amended) The method of claim 33, wherein the at least one viral glycoprotein is the fusion gene glycoprotein of NDV~~31, wherein a combination of polypeptides is administered to the patient, wherein the combination includes an isolated polynucleotide encoding the F glycoprotein of Newcastle Disease Virus and an isolated polynucleotide encoding the HN glycoprotein of Newcastle Disease Virus~~.
35. (Currently Amended) The method of claim 33, wherein the at least one viral glycoprotein is the hemagglutinin-neuraminidase glycoprotein of NDV ~~31, which comprises administering to the patient at least one vector that comprises the at least one isolated polynucleotide encoding at least one viral polypeptide, or an analog or subunit thereof having oncolytic activity~~.
36. (Currently Amended) The method of claim 35, ~~wherein the vector is a viral vector~~~~—33~~ further comprising the [[F]] fusion gene glycoprotein and hemagglutinin-neuraminidase [[HN]] glycoprotein of NDV.
37. (Currently Amended) The method of claim 33 further comprising the [[F]] fusion gene glycoprotein and hemagglutinin-neuraminidase [[HN]] glycoprotein of NDV ~~A method of making a cancer treatment composition which comprises incorporating in the composition an isolated viral glycoprotein or a subunit or analog thereof having oncolytic activity or of an isolated polynucleotide encoding the same~~.
38. (New) The method of claim 33, wherein the viral glycoprotein is from a velogenic strain of NDV.
39. (New) The method of claim 33, wherein the viral glycoprotein is from a mesogenic strain of NDV.
40. (New) The method of claim 33, wherein the viral glycoprotein is from a lentogenic strain of NDV.
41. (New) The method of claim 39, wherein the lentogenic strain of NDV is the HUI strain.

42. (New) The method of claim 31, wherein the step of administering is selected from intravenous, oral, buccal, intranasal, inhalation, topical application to a mucosal membrane or injection including intradermal, intrathecal, intracisternal, and intralesional injection.
43. (New) The method of claim 31, wherein the step of administering comprises locally administering the composition to a tumor or in its vicinity.
44. (New) The method of claim 32, wherein the composition comprises  $10^6 - 10^{12}$  EID<sub>50</sub> per unit dose.
45. (New) The method of claim 32, wherein the step of administering comprises administering the HUI strain of NDV in a range of 20 EID<sub>50</sub>/cell to 2000 EID<sub>50</sub>/cell.
46. (New) A method for treating cancer in a patient comprising administering to the patient in need thereof at least one isolated polynucleotide encoding at least one viral polypeptide, an analog or subunit thereof having oncolytic activity.
47. (New) The method of claim 45, wherein the at least one isolated polynucleotide encodes the fusion gene glycoprotein of Newcastle Disease Virus.
48. (New) The method of claim 45, wherein the at least one isolated polynucleotide encodes the hemagglutinin-neuraminidase glycoprotein of Newcastle Disease Virus.
49. (New) The method of claim 45, wherein a combination of polynucleotides is administered to the patient, wherein the combination includes an isolated polynucleotide encoding the fusion gene of Newcastle Disease Virus (NDV) and an isolated polynucleotide encoding the hemagglutinin-neuraminidase glycoprotein of NDV.
50. (New) The method of claim 45, which comprises administering to the patient at least one vector that comprises the at least one isolated polynucleotide encoding at least one viral polypeptide, or an analog or subunit thereof having oncolytic activity.
51. (New) The method of claim 49, wherein the vector is a viral vector.
52. (New) The method of claim 49, wherein the vector is an expression vector.

53. (New) A method for treating cancer in a patient comprising administering to the patient in need thereof a host cell transfected with an isolated polynucleotide, the isolated polynucleotide encodes at least one viral polypeptide, an analog, or subunit thereof having oncolytic activity, the at least one viral polypeptide or an analog or subunit thereof being expressed in the host cell.
54. (New) A method for treating cancer in a patient comprising administering to the patient in need thereof a host cell transfected with a vector, the vector comprising an isolated polynucleotide encoding at least one viral polypeptide or an analog or subunit thereof having oncolytic activity, wherein the at least one viral polypeptide or an analog or subunit thereof being expressed in the host cell.
55. (New) A method of making a cancer treatment composition which comprises incorporating in the composition an isolated viral glycoprotein or a subunit or analog thereof having oncolytic activity or of an isolated polynucleotide encoding the same.